# Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece

> **NCT03780504** · — · UNKNOWN · sponsor: **Genesis Pharma S.A.** · enrollment: 170 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03780504
- **Lead sponsor:** Genesis Pharma S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-15
- **Primary completion:** 2021-07-20
- **Final completion:** 2022-12-31
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2021-12-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03780504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03780504, "Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03780504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*